Jazz Pharmaceuticals plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| J7Z.F | LGND | XENE | 4565.T | ZLAB | ZVRA | |
|---|---|---|---|---|---|---|
| Market cap | 13.11B | 6.32B | 3.80B | 158.60B | 2.83B | 663.32M |
| P/E (TTM) | 70.2 | 127.0 | — | — | — | 9.2 |
| Forward P/E | 11.6 | 25.9 | -8.3 | 38.6 | -10.9 | 10.4 |
| Price/book | 3.5 | 6.6 | 3.1 | 2.5 | 4.2 | 2.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +78.75% | +51.82% | +2.32% | +93.88% | −1.51% | +22.88% |
| Today | −1.73% | +0.83% | +2.51% | +13.75% | +3.83% | +8.87% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All J7Z.F news ›Major Portfolio Expansion Brings New Hope for Epilepsy and HER2+ GEA Patients – Jazz Pharmaceuticals
Jazz Pharmaceuticals shared on LinkedIn: “We reported our third quarter 2026 results today, reflecting continued progress across our commercial and R and D portfolio. We expanded our rare epilepsy portfolio through the acquisition of Actio…
Jazz Pharmaceuticals Non-GAAP EPS of -$3.88 misses by $1.50, revenue of $1.24B beats by $30M
Jazz Pharmaceuticals Q3 results: EPS missed, revenue beat, and 2026 revenue guidance was raised. - Jazz Pharmaceuticals press release (JAZZ): Q3 Non-GAAP EPS of -$3.88 misses by $1.50. - Revenue of $1.24B (+9.7% Y/Y) beats by $30M.
Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) – – Company raises full year 2026 total revenue guidance – – Ziihera® launched in HER2+ 1L mGEA – – Xywav® revenues grew 12% YoY with 425 net patient…
More from 1 other outlet
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST John Bluth - Head of Investor RelationsRenée Galá - President, CEO & DirectorSamantha Pearce - Executive VP & Chief Commercial OfficerRobert Iannone -…
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
PR Newswire DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: - Jefferies London Global H
Jazz Pharmaceuticals (JAZZ) shares skyrocket, what you need to know
Shares of biopharma company Jazz Pharmaceuticals JAZZjumped 8.4% in the afternoon session after the company reported record revenue in its third-quarter 2026 financial results and increased its full-year 2026 total revenue outlook. What is…
Citi Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Citi analyst Geoff Meacham maintained a Buy rating on Jazz Pharmaceuticals today and set a price target of $325.00. According to TipRanks, Meacham is a 5-star analyst with an average return of 14.3% and a 57.71% success rate. Meacham…
Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Target Raised at Royal Bank Of Canada
Posted by Danessa Lincoln on Nov 3rd, 2026 Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its price objective hoisted by Royal Bank Of Canada from $296.00 to $305.00 in a research note issued on Tuesday, Benzinga reports. The…
Jazz Pharmaceuticals (NASDAQ:JAZZ) Announces Quarterly Earnings Results
Posted by Sarita Garza on Nov 3rd, 2026 Here are the key takeaways from Jazz Pharmaceuticals’ conference call: Get Our Latest Stock Report on JAZZ Here are the key news stories impacting Jazz Pharmaceuticals this week: Jazz’s sleep…
Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026
Nov 02, 2026, 08:30 ET Presentations showcase Phase 3 ACTION trial progress and continued development of novel therapies for rare brain cancers For U.S. media and investors only DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com7
- prnewswire.com4
- stocktitan.net4
- tradingview.com4
- news.alphastreet.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 30 articles, not a forecast.